Stock AnalizBeOne Medicines Ltd. ONC
Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026
BeOne Medicines Ltd. (ONC) is a healthcare company listed in the US with a market value of about $47.6B. In the twelve months to September 30, 2026 it had revenue of $6.6B and net income of $916M, a net margin of 13.9%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is financial health (5/5); the weakest is value (0/5).
Key numbers: a P/E of 52.8, a price to free cash flow of 32.8, 5-year revenue growth of 77% a year, a 5-year average ROIC of -14%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 85% below the current price.
Score: 2.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.6B | $5.3B | $3.8B | $2.5B | $1.4B | $1.2B | $309M | $428M | $198M | $238M | $1M |
| Net income | $916M | $287M | -$645M | -$882M | -$2.0B | -$1.5B | -$1.6B | -$949M | -$674M | -$93M | -$119M |
| Free cash flow | $1.4B | $942M | -$633M | -$1.7B | -$1.8B | -$1.6B | -$1.4B | -$840M | -$618M | -$34M | -$113M |
| EPS (diluted) | $7.88 | $0.19 | $-0.47 | $-0.65 | $-1.49 | $-1.21 | $-1.50 | $-1.22 | $-0.93 | $-0.16 | $-0.30 |
| Net margin | 13.9% | 5.4% | -16.9% | -35.9% | -141.5% | -123.9% | -526.1% | -221.5% | -339.9% | -39.1% | -11141.8% |
| ROIC | — | 5.6% | -10.2% | -21.4% | -28.4% | -16.7% | -29.5% | -70.1% | -38.0% | -11.3% | -25.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 27 analysts is $465.00, 12% above the current price; targets range from $385.00 to $561.30; the consensus rating is “Strong buy”; expected EPS is $9.87 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is BeOne Medicines’s P/E ratio?
About 52.8, based on the last twelve months of diluted earnings per share (forward P/E about 41.6).
Is BeOne Medicines stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 85% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does BeOne Medicines pay a dividend?
Not currently.
Is BeOne Medicines a good stock to buy?
We do not give buy or sell advice. BeOne Medicines scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.